Table 1 Baseline characteristics of recurrent myocardial infarction in patients with myocardial infarction.
Variables | Whether myocardial infarction recurred | ||
|---|---|---|---|
NO N = 2224 | YES N = 1583 | P-value | |
Demographics | |||
Male, N (%) | 1566 (70.41%) | 1150 (72.65%) | 0.133 |
Age, years | 66.42 ± 12.19 | 65.56 ± 12.07 | 0.032 |
BMI, kg/m2 | 19.71 ± 3.04 | 19.74 ± 3.11 | 0.786 |
Medical history, N (%) | |||
Auricular fibrillation | 192 (8.63%) | 146 (9.22%) | 0.528 |
V alvular heart disease | 419 (18.84%) | 302 (19.08%) | 0.854 |
Previous myocardial infarction | 166 (7.46%) | 54 (3.41%) | < 0.001 |
Hypertension | 1504 (67.63%) | 1029 (65.00%) | 0.091 |
Diabetes mellitus | 771 (34.67%) | 504 (31.84%) | 0.068 |
COPD | 456 (20.50%) | 337 (21.29%) | 0.557 |
Renal insufficiency | 471 (21.18%) | 364 (22.99%) | 0.182 |
Stroke | 375 (16.86%) | 260 (16.42%) | 0.721 |
Clinical conditions at admission | |||
LVEF, % | 53.70 ± 12.56 | 51.47 ± 10.76 | < 0.001 |
NTproBNP, pg/ml | 3210.11 ± 6690.12 | 4110.36 ± 8008.28 | < 0.001 |
Troponin T, ng/mL | 2.89 ± 2.86 | 3.17 ± 2.91 | 0.004 |
Low-density Lipoprotein, mmol/L | 2.70 ± 0.96 | 2.81 ± 0.93 | < 0.001 |
Myocardial infarction classification, N (%) | < 0.001 | ||
NSTEMI | 1510 (67.90%) | 752 (47.50%) | |
STEMI | 714 (32.10%) | 831 (52.50%) | |
Pulmonary infection, N (%) | 548 (24.64%) | 509 (32.15%) | < 0.001 |
Killip classification, N (%) | 0.531 | ||
1 | 651 (29.27%) | 470 (29.69%) | |
2 | 816 (36.69%) | 546 (34.49%) | |
3 | 437 (19.65%) | 331 (20.91%) | |
4 | 320 (14.39%) | 236 (14.91%) | |
Treatment, N (%) | |||
PCI | 1700 (76.44%) | 1340 (84.65%) | < 0.001 |
Antiplatelet drugs | 2195 (98.70%) | 1571 (99.24%) | 0.108 |
Number of antiplatelet agents | < 0.001 | ||
0 | 29 (1.30%) | 12 (0.76%) | |
1 | 82 (3.69%) | 20 (1.26%) | |
2 | 1628 (73.20%) | 1155 (72.96%) | |
3 | 444 (19.96%) | 361 (22.80%) | |
4 | 38 (1.71%) | 34 (2.15%) | |
5 | 3 (0.13%) | 1 (0.06%) | |
Statins | 2193 (98.61%) | 1568 (99.05%) | 0.214 |
β-blockers | 1950 (87.68%) | 1418 (89.58%) | 0.071 |
Novel oral anticoagulants | 68 (3.06%) | 49 (3.10%) | 0.947 |
Warfarin | 18 (0.81%) | 9 (0.57%) | 0.383 |
Antibiotics | 569 (25.58%) | 528 (33.35%) | < 0.001 |
